News

A Mayo Clinic study found that pancreatic cysts with multiple concerning features may carry a greater risk of progressing to pancreatic cancer or advanced precancerous changes. The three-year risk increased from approximately 2% with one concerning feature to 18% with three or more. The findings may help specialists identify who needs closer monitoring or treatment while allowing patients at lower risk to avoid unnecessary pancreatic surgery.

A small study suggests that early, personalized nutrition support may help patients with pancreatic cancer tolerate more of their prescribed chemotherapy and recover more quickly after surgery. Patients who worked closely with a dietitian had higher chemotherapy completion, shorter hospital stays, and fewer postoperative infections. Although larger studies are needed, the findings support making nutrition an early and ongoing part of pancreatic cancer care.

A new feasibility study found that ultrasound-guided progressive pneumoperitoneum (PPP) allowed patients with "non-accessible" abdomens to safely receive PIPAC, a treatment for peritoneal carcinomatosis. While only five patients were studied, all successfully underwent PIPAC without major complications, suggesting this technique may expand treatment options for selected patients.

Peritoneal metastases are difficult to treat because standard IV chemotherapy often cannot reach tumors inside the abdomen effectively. This review explores NIPS, an approach that combines intravenous chemotherapy with repeated chemotherapy delivered directly into the abdominal cavity. Early research—especially in gastric cancer—suggests this strategy may improve disease control, increase eligibility for surgery, and help some patients live longer.

Pancreatic cancer that has spread to the lining of the abdomen (called the peritoneum) is often difficult to treat and is associated with poor outcomes. Standard treatment typically involves chemotherapy, but survival rates remain low. Researchers conducted a systematic review to examine whether a treatment approach called cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) may improve outcomes for some patients with pancreatic cance

Pancreatic cancer that has spread to the abdominal lining is typically treated with palliative chemotherapy, and outcomes remain poor. A new study examined whether a more aggressive strategy—surgery to remove visible tumors followed by heated chemotherapy delivered directly into the abdomen (HIPEC)—could improve survival in carefully selected patients. The findings offer insight into a potential new approach for managing advanced disease.

Brianna M. Krusen, Phyllis A. Gimotty, Greg Donahue, Jacob E. Till, Melinda Yin, Erin E. Carlson, William R. Bamlet, Erica L. Carpenter, Shounak Majumder, Ann L. Oberg, Kenneth S. Zaret; Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor (PIGR). Clin Cancer Res 15 February 2026; 32 (4): 756–769. https://doi.org/10.1158/1078-0432.CCR-25-3297 Why This Matters Pancreatic